Cipla misses second-quarter profit estimates on muted US sales
FROM THE WIRE · THEHINDUBUSINESSLINE.COM
Cipla, the country's third-largest drugmaker by revenue, missed second-quarter profit estimates on Tuesday, as muted sales of generic Revlimid and stiff competition weighed on its US business.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA profit miss by a major Indian drugmaker weighs on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Cipla missed second-quarter profit estimates.
- 02Sales of generic Revlimid were muted.
- 03Stiff competition weighed on its US business.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets